The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Neurology Clinical Trials Market Projected To Reach By 2030?
The neurology clinical trials market has experienced substantial growth in recent years. It is projected to expand from $5.8 billion in 2025 to $6.21 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. The expansion observed in the past can be attributed to the rising prevalence of neurological diseases, the broadening of pharmaceutical research pipelines, increased investment in the development of neurology drugs, the accessibility of advanced imaging tools, and a surge in participation in clinical research.
The neurology clinical trials market size is anticipated to undergo significant growth in the upcoming years. It is projected to expand to $8.05 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.7%. This expansion during the forecast period is propelled by the enhanced utilization of AI-driven trial analytics, an escalated demand for quicker trial execution, the proliferation of patient-centric trial models, augmented integration of remote monitoring technologies, and a heightened emphasis on rare neurological conditions. Major trends for the forecast period encompass a greater uptake of adaptive clinical trial designs, increased application of digital patient monitoring tools, a deepening focus on biomarker-based neurology trials, the continued expansion of decentralized clinical trial models, and a strong emphasis on generating real-world evidence.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25847&type=smp
Which Primary Drivers Are Impacting The Neurology Clinical Trials Market Growth?
The growth of the neurology clinical trials market is projected to be propelled by the escalating occurrence of neurological disorders. These conditions involve the brain, spinal cord, or nerves, thereby disrupting the nervous system’s regular function. The rise in neurological disorders is mainly attributed to the aging demographic, as older adults are more prone to age-related ailments like Alzheimer’s and Parkinson’s disease. Neurology clinical trials play a vital role in managing neurological disorders by testing new treatments, drugs, or interventions designed to enhance diagnosis, alleviate symptoms, slow down disease progression, and improve patient results. For example, in September 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, projected that the population of Australians afflicted with dementia is anticipated to more than double, increasing from 411,100 in 2023 to 849,300 by 2058. Furthermore, by 2058, an estimated 315,500 men and 533,800 women are expected to be living with dementia. Consequently, the increasing prevalence of neurological disorders is a primary driver for the expansion of the neurology clinical trials market.
Which Segment Classifications Are Used In The Neurology Clinical Trials Market Segment Analysis?
The neurology clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Study Design: Interventional, Observational, Expanded Access
3) By Indication: Epilepsy, Parkinson’s Disease (PD), Huntington’s Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Other Indications
4) By End-User: Hospitals, Clinics, Research Institutes, Other End- Users
Subsegments:
1) By Phase I: Drug Safety Evaluation, Pharmacokinetics Assessment, Dosage Range Finding, Tolerability Studies
2) By Phase II: Efficacy Evaluation, Dose Response Studies, Therapeutic Effectiveness, Biomarker Identification
3) By Phase III: Large Scale Efficacy Studies, Safety Monitoring, Comparative Effectiveness, Risk Benefit Analysis
4) By Phase IV: Post Marketing Surveillance, Long Term Safety Follow Up, Real World Evidence Collection, Quality Of Life Assessment
Which Trends Are Shaping Growth In The Neurology Clinical Trials Market?
Leading firms within the neurology clinical trials market are concentrating on creating advanced solutions, particularly monoclonal antibodies, aiming to precisely address neurological pathways, enhance treatment effectiveness, and speed up the creation of new therapeutic options. A monoclonal antibody, by definition, is a laboratory-created molecule specifically designed to identify and attach to particular proteins or antigens, frequently employed for its high precision in targeting disease mechanisms within both therapeutic and diagnostic applications. Illustratively, in July 2024, Eli Lilly and Company, a pharmaceutical firm based in the U.S., introduced Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer’s disease. This medication is designed to decelerate cognitive and functional deterioration, thereby providing eligible patients with an extended period of independence and participation in their daily routines. It operates by targeting and diminishing brain amyloid plaques; clinical studies have indicated up to a 35% reduction in disease advancement compared to a placebo for individuals with less severe forms of the condition.
Which Firms Are Contributing To The Neurology Clinical Trials Market Ecosystem?
Major companies operating in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, Lindus Health Ltd.
Get The Full Neurology Clinical Trials Market Report:
https://www.thebusinessresearchcompany.com/report/neurology-clinical-trials-global-market-report
Which Region Dominates The Neurology Clinical Trials Market By Market Share?
North America was the largest region in the neurology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Neurology Clinical Trials Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/neurology-clinical-trials-global-market-report
Browse Through More Reports Similar to the Global Neurology Clinical Trials Market 2026, By The Business Research Company
Interventional Neurology Devices And Equipment Market Report 2026
Neuroprosthetics Market Report
https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report
Neuroscience Antibodies And Assays Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model